CO6852025A2 - El anticuerpo neutralizador del receptor de prolactina mat3 y su uso terapéutico - Google Patents

El anticuerpo neutralizador del receptor de prolactina mat3 y su uso terapéutico

Info

Publication number: CO6852025A2
Authority: CO; Colombia
Prior art keywords: mat3; therapeutic use; neutralizing antibody; prolactin receptor; prolactin
Prior art date: 2011-06-03

Application number

CO13283823A

Other languages

English (en)

Inventor

Christoph Freiberg

Christiane Otto

Lars Linden

Axel Harrenga

Mark Trautwein

Simone Greven

Andreas Wilmen

Original Assignee

Bayer Ip Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-06-03

Filing date

2013-12-03

Publication date

2014-01-30

2013-12-03 Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh

2014-01-30 Publication of CO6852025A2 publication Critical patent/CO6852025A2/es

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3015—Breast
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Endocrinology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Epidemiology (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Mycology (AREA)
Microbiology (AREA)
Diabetes (AREA)
Reproductive Health (AREA)
Cell Biology (AREA)
Dermatology (AREA)
Urology & Nephrology (AREA)
Gynecology & Obstetrics (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

CO13283823A 2011-06-03 2013-12-03 El anticuerpo neutralizador del receptor de prolactina mat3 y su uso terapéutico CO6852025A2 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP11168644A EP2530089A1 (en)	2011-06-03	2011-06-03	Neutralising prolactin receptor antibody Mat3 and its therapeutical use

Publications (1)

Publication Number	Publication Date
CO6852025A2 true CO6852025A2 (es)	2014-01-30

Family

ID=46331236

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CO13283823A CO6852025A2 (es)	2011-06-03	2013-12-03	El anticuerpo neutralizador del receptor de prolactina mat3 y su uso terapéutico

Country Status (37)

Country	Link
US (2)	US9353186B2 (es)
EP (2)	EP2530089A1 (es)
JP (1)	JP5859641B2 (es)
KR (1)	KR101920521B1 (es)
CN (1)	CN103764679B (es)
AP (1)	AP2013007266A0 (es)
AR (1)	AR086631A1 (es)
AU (1)	AU2012264765B2 (es)
BR (1)	BR112013030995B1 (es)
CA (1)	CA2837736C (es)
CL (1)	CL2013003459A1 (es)
CO (1)	CO6852025A2 (es)
CR (1)	CR20130632A (es)
CU (1)	CU20130163A7 (es)
CY (1)	CY1117660T1 (es)
DK (1)	DK2714740T3 (es)
DO (1)	DOP2013000285A (es)
EA (1)	EA029316B1 (es)
EC (1)	ECSP13013063A (es)
ES (1)	ES2572215T3 (es)
HK (1)	HK1195081A1 (es)
HR (1)	HRP20160506T1 (es)
HU (1)	HUE028775T2 (es)
IL (1)	IL229504B (es)
MA (1)	MA35237B1 (es)
ME (1)	ME02659B (es)
MX (1)	MX343683B (es)
PE (1)	PE20141158A1 (es)
PL (1)	PL2714740T3 (es)
RS (1)	RS54727B1 (es)
SG (1)	SG195060A1 (es)
SI (1)	SI2714740T1 (es)
TN (1)	TN2013000501A1 (es)
TW (1)	TWI548649B (es)
UY (1)	UY34116A (es)
WO (1)	WO2012163932A1 (es)
ZA (1)	ZA201309683B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP3421488A3 (en)	2012-03-14	2019-04-17	Regeneron Pharmaceuticals, Inc.	Multispecific antigen-binding molecules and uses thereof
PL2935331T3 (pl) *	2012-12-24	2018-07-31	Abbvie Inc.	Białka wiążące receptor prolaktyny i ich zastosowania
US9545451B2 (en)	2013-08-21	2017-01-17	Regeneron Pharmaceuticals, Inc.	Anti-PRLR antibodies and methods for killing PRLR-expressing cells
TWI641620B (zh)	2013-08-21	2018-11-21	再生元醫藥公司	抗－ｐｒｌｒ抗體及其用途
IL296285A (en)	2015-07-06	2022-11-01	Regeneron Pharma	Multispecific antigen binding molecules and their uses
EP3448891A1 (en)	2016-04-28	2019-03-06	Regeneron Pharmaceuticals, Inc.	Methods of making multispecific antigen-binding molecules
EA201900312A1 (ru)	2016-11-29	2019-12-30	Регенерон Фармасьютикалз, Инк.	Способы лечения пролактин-рецептор положительного рака молочной железы
TW201836647A (zh)	2017-04-06	2018-10-16	美商艾伯維有限公司	抗－ｐｒｌｒ抗體藥物軛合物（ａｄｃ）及其用途
KR20200027494A (ko)	2017-07-10	2020-03-12	바이엘 파마 악티엔게젤샤프트	남성 및 여성 패턴 탈모를 위한 프로락틴 수용체 항체
TW201910349A (zh) *	2017-08-10	2019-03-16	美商格里佛診斷方法股份有限公司	包含重組人類ｃｄ３８細胞外區域之組合物、方法及／或套組
CN112040985A (zh)	2018-02-07	2020-12-04	瑞泽恩制药公司	用于递送治疗性蛋白质的方法和组合物
AR124681A1 (es)	2021-01-20	2023-04-26	Abbvie Inc	Conjugados anticuerpo-fármaco anti-egfr
CN116655791B (zh) *	2023-05-06	2023-11-07	浙江触奇生物科技有限公司	一种抗泌乳素受体的纳米抗体、重组载体、重组菌和应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4657760A (en)	1979-03-20	1987-04-14	Ortho Pharmaceutical Corporation	Methods and compositions using monoclonal antibody to human T cells
US4634665A (en)	1980-02-25	1987-01-06	The Trustees Of Columbia University In The City Of New York	Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en)	1980-02-25	1993-01-12	The Trustees Of Columbia University In The City Of New York	Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en)	1980-02-25	1983-08-16	The Trustees Of Columbia University	Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en)	1982-11-18	1985-04-09	Chiron Corporation	Adenovirus promoter system
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US5168062A (en)	1985-01-30	1992-12-01	University Of Iowa Research Foundation	Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US5206344A (en)	1985-06-26	1993-04-27	Cetus Oncology Corporation	Interleukin-2 muteins and polymer conjugation thereof
US4968615A (en)	1985-12-18	1990-11-06	Ciba-Geigy Corporation	Deoxyribonucleic acid segment from a virus
US5225212A (en)	1989-10-20	1993-07-06	Liposome Technology, Inc.	Microreservoir liposome composition and method
JP4157160B2 (ja)	1991-12-13	2008-09-24	ゾーマテクノロジーリミテッド	改変抗体可変領域の調製のための方法
JP4436457B2 (ja)	1995-08-18	2010-03-24	モルフォシスアイピーゲーエムベーハー	蛋白質／（ポリ）ペプチドライブラリー
GB9701425D0 (en)	1997-01-24	1997-03-12	Bioinvent Int Ab	A method for in vitro molecular evolution of protein function
WO2003008583A2 (en)	2001-03-02	2003-01-30	Sagres Discovery	Novel compositions and methods for cancer
AU2002322280A1 (en)	2001-06-21	2003-01-21	Millennium Pharmaceuticals, Inc.	Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
EP1325930A1 (en) *	2002-01-08	2003-07-09	Institut National De La Sante Et De La Recherche Medicale (Inserm)	Mammal prolactin variants
WO2006110585A2 (en)	2005-04-07	2006-10-19	Novartis Vaccines And Diagnostics Inc.	Cancer-related genes (prlr)
US7422899B2 (en)	2005-10-05	2008-09-09	Biogen Idec Ma Inc.	Antibodies to the human prolactin receptor
EP2059535B1 (en)	2006-08-18	2013-11-06	Novartis AG	Prlr-specific antibody and uses thereof
EP2332995A1 (en) *	2009-12-10	2011-06-15	Bayer Schering Pharma Aktiengesellschaft	Neutralizing prolactin receptor antibodies and their therapeutic use

2011
- 2011-06-03 EP EP11168644A patent/EP2530089A1/en not_active Withdrawn
2012
- 2012-05-31 BR BR112013030995-4A patent/BR112013030995B1/pt active IP Right Grant
- 2012-05-31 ME MEP-2016-91A patent/ME02659B/me unknown
- 2012-05-31 RS RS20160322A patent/RS54727B1/sr unknown
- 2012-05-31 EP EP12729030.2A patent/EP2714740B1/en active Active
- 2012-05-31 PE PE2013002749A patent/PE20141158A1/es active IP Right Grant
- 2012-05-31 EA EA201301356A patent/EA029316B1/ru not_active IP Right Cessation
- 2012-05-31 CN CN201280038107.4A patent/CN103764679B/zh active Active
- 2012-05-31 ES ES12729030T patent/ES2572215T3/es active Active
- 2012-05-31 MX MX2013014174A patent/MX343683B/es active IP Right Grant
- 2012-05-31 HU HUE12729030A patent/HUE028775T2/en unknown
- 2012-05-31 KR KR1020137034848A patent/KR101920521B1/ko active IP Right Grant
- 2012-05-31 PL PL12729030T patent/PL2714740T3/pl unknown
- 2012-05-31 DK DK12729030.2T patent/DK2714740T3/da active
- 2012-05-31 SG SG2013085816A patent/SG195060A1/en unknown
- 2012-05-31 US US14/123,517 patent/US9353186B2/en active Active
- 2012-05-31 AP AP2013007266A patent/AP2013007266A0/xx unknown
- 2012-05-31 JP JP2014513160A patent/JP5859641B2/ja active Active
- 2012-05-31 WO PCT/EP2012/060078 patent/WO2012163932A1/en active Application Filing
- 2012-05-31 CA CA2837736A patent/CA2837736C/en active Active
- 2012-05-31 AU AU2012264765A patent/AU2012264765B2/en active Active
- 2012-05-31 SI SI201230553A patent/SI2714740T1/sl unknown
- 2012-06-01 UY UY0001034116A patent/UY34116A/es not_active Application Discontinuation
- 2012-06-01 AR ARP120101933A patent/AR086631A1/es active Pending
- 2012-06-01 TW TW101119849A patent/TWI548649B/zh active
2013
- 2013-11-19 IL IL229504A patent/IL229504B/en active IP Right Grant
- 2013-12-02 MA MA36513A patent/MA35237B1/fr unknown
- 2013-12-02 TN TNP2013000501A patent/TN2013000501A1/fr unknown
- 2013-12-03 EC ECSP13013063 patent/ECSP13013063A/es unknown
- 2013-12-03 CU CU2013000163A patent/CU20130163A7/es unknown
- 2013-12-03 CO CO13283823A patent/CO6852025A2/es not_active Application Discontinuation
- 2013-12-03 CL CL2013003459A patent/CL2013003459A1/es unknown
- 2013-12-03 DO DO2013000285A patent/DOP2013000285A/es unknown
- 2013-12-03 CR CR20130632A patent/CR20130632A/es unknown
- 2013-12-20 ZA ZA2013/09683A patent/ZA201309683B/en unknown
2014
- 2014-08-18 HK HK14108441.2A patent/HK1195081A1/zh unknown
2016
- 2016-04-28 US US15/140,629 patent/US9777063B2/en active Active
- 2016-05-12 HR HRP20160506TT patent/HRP20160506T1/hr unknown
- 2016-06-17 CY CY20161100549T patent/CY1117660T1/el unknown

Also Published As

Publication number	Publication date
ECSP13013063A (es)	2014-01-31
PE20141158A1 (es)	2014-09-26
AU2012264765B2 (en)	2016-07-28
UY34116A (es)	2013-01-03
CL2013003459A1 (es)	2014-08-08
CU20130163A7 (es)	2014-04-24
AR086631A1 (es)	2014-01-08
EA201301356A1 (ru)	2014-09-30
ME02659B (me)	2017-06-20
EP2714740A1 (en)	2014-04-09
MX2013014174A (es)	2014-11-13
PL2714740T3 (pl)	2016-08-31
TWI548649B (zh)	2016-09-11
JP2014522239A (ja)	2014-09-04
HK1195081A1 (zh)	2014-10-31
TW201302798A (zh)	2013-01-16
CY1117660T1 (el)	2017-05-17
IL229504A0 (en)	2014-01-30
CR20130632A (es)	2014-02-04
US9353186B2 (en)	2016-05-31
ZA201309683B (en)	2016-08-31
HUE028775T2 (en)	2017-01-30
AU2012264765A1 (en)	2013-12-19
RS54727B1 (sr)	2016-10-31
KR101920521B1 (ko)	2018-11-21
ES2572215T3 (es)	2016-05-30
CN103764679B (zh)	2016-05-04
EP2714740B1 (en)	2016-03-30
WO2012163932A1 (en)	2012-12-06
SG195060A1 (en)	2013-12-30
AP2013007266A0 (en)	2013-11-30
JP5859641B2 (ja)	2016-02-10
SI2714740T1 (sl)	2016-06-30
DOP2013000285A (es)	2014-03-16
DK2714740T3 (da)	2016-05-30
EA029316B1 (ru)	2018-03-30
IL229504B (en)	2018-10-31
US20140141003A1 (en)	2014-05-22
BR112013030995B1 (pt)	2021-11-09
CA2837736A1 (en)	2012-12-06
KR20140036275A (ko)	2014-03-25
US9777063B2 (en)	2017-10-03
EP2530089A1 (en)	2012-12-05
CN103764679A (zh)	2014-04-30
TN2013000501A1 (en)	2015-03-30
US20160319029A1 (en)	2016-11-03
MA35237B1 (fr)	2014-07-03
BR112013030995A2 (pt)	2016-11-22
MX343683B (es)	2016-11-17
CA2837736C (en)	2018-11-20
HRP20160506T1 (hr)	2016-06-17
NZ618316A (en)	2016-01-29

Legal Events

Date	Code	Title	Description
2015-02-20	FC	Application refused

Publication	Publication Date	Title
CO6852025A2 (es)	2014-01-30	El anticuerpo neutralizador del receptor de prolactina mat3 y su uso terapéutico
LTPA2018511I1 (lt)	2018-10-10	Policikliniai karbamoilpiridino junginiai ir jų farmacinis panaudojimas
IL270347B (en)	2021-08-31	Therapeutically active compounds and methods of use
HK1217948A1 (zh)	2017-01-27	治療活性化合物及其使用方法
CO6870033A2 (es)	2014-02-20	Compuestos terapéuticos y métodos de uso relacionados
ECSP12011965A (es)	2012-07-31	Anticuerpos neutralizadores contra el receptor de prolactina y su uso terapéutico
CO7030962A2 (es)	2014-08-21	Compuestos terapéuticamente activos y sus métodos de uso
CO7010834A2 (es)	2014-07-31	Compuestos terapéuticamente activos y sus métodos de uso
CO6862157A2 (es)	2014-02-10	Compuestos de tetrahidropirido-piridina y tetrahidropirido-pirimida y su uso como moduladores de receptoresde c5a
BR112014001030A2 (pt)	2017-07-04	anticorpos anti-receptor alfa de folato e usos destes
CO6821893A2 (es)	2013-12-31	Uso del anticuerpo anti-cd19 inmunoconjugado con maitansinoide para el tratamiento del síntoma tumores de células b
CO6950473A2 (es)	2014-05-20	Novedosos derivados de purina y su uso en el tratamiento de enfermedades
CO7020870A2 (es)	2014-08-11	Anticuerpos anti-htra1 y métodos de uso
HK1223924A1 (zh)	2017-08-11	治療活性化合物及其使用方法
CO7000747A2 (es)	2014-07-21	Anticuerpos anti-lrp5 y métodos de uso
CO7000778A2 (es)	2014-07-21	Derivados de pirazolopiridina, su procedimiento de preparación y su uso terapéutico
BR112013022552A2 (pt)	2016-12-06	compostos de quinazolina substituídos com alcino e métodos de uso
SMT201500296B (it)	2016-01-08	Antagonisti del recettore trpm8
BR112014010774A2 (pt)	2017-06-13	anticorpos anti-kdr e métodos de uso
CO6900142A2 (es)	2014-03-20	Derivados de etinilo como moduladores del receptor metatrópico de glutamato
BR112014013746A2 (pt)	2017-06-13	aparelho de descarga e uso do aparelho de descarga
CO6880061A2 (es)	2014-02-28	Método para tratar el cáncer mediante el uso combinado de fármacos
CO7020916A2 (es)	2014-08-11	Utilizacion en terapeutica de derivados de imidazopiridina
ES1077262Y (es)	2012-09-21	Dispositivo de ayuda para el uso de dispositivos táctiles
CO6990740A2 (es)	2014-07-10	Nuevo uso terapéutico de antagonistas de receptor p75